Galectin Therapeutics (GALT) Tops Q2 EPS by 4c

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance
• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance